Genentech's Acquisition Of Tanox Does Not Represent A Strategic Shift, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech will continue to set a "high bar" for acquisitions after buying Xolair partner Tanox for $919 mil., firm says.
You may also be interested in...
Genentech Product Sales Rise 18 Percent, Led By Avastin, Though Lucentis A Disappointment
Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .
Genentech Product Sales Rise 18 Percent, Led By Avastin, Though Lucentis A Disappointment
Firm would bid on remaining rights to Rituxan should a change of control occur at Biogen Idec, CFO Ebersman says during third quarter call .
Genentech’s Tanox Acquisition Delayed Due to FTC Information Request
Firms expect $919 million deal to close by mid-year.